Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Ischemic Heart Disease

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 201 articles:
HTML format
Text format



Single Articles


    July 2019
  1. MOK Y, Sang Y, Ballew SH, Hoogeveen RC, et al
    Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction.
    Am Heart J. 2019;216:62-73.
    PubMed     Text format     Abstract available


  2. MAURI L, Doros G, Rao SV, Cohen DJ, et al
    The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale.
    Am Heart J. 2019;216:82-90.
    PubMed     Text format     Abstract available


  3. FARIDI KF, Rymer JA, Rao SV, Dai D, et al
    Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry.
    Am Heart J. 2019;216:53-61.
    PubMed     Text format     Abstract available


  4. FU EL, Franko MA, Obergfell A, Dekker FW, et al
    High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients.
    Am Heart J. 2019;216:20-29.
    PubMed     Text format     Abstract available


    June 2019
  5. WEBER B, Bersch-Ferreira AC, Torreglosa CR, Marcadenti A, et al
    Implementation of a Brazilian Cardioprotective Nutritional (BALANCE) Program for improvement on quality of diet and secondary prevention of cardiovascular events: A randomized, multicenter trial.
    Am Heart J. 2019;215:187-197.
    PubMed     Text format     Abstract available


  6. KUKULA K, Urbanowicz A, Klopotowski M, Dabrowski M, et al
    Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease.
    Am Heart J. 2019;215:78-82.
    PubMed     Text format     Abstract available


  7. JOSHI R, Agrawal T, Fathima F, Usha T, et al
    Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial.
    Am Heart J. 2019;216:9-19.
    PubMed     Text format     Abstract available


  8. MEHTA SR, Wood DA, Meeks B, Storey RF, et al
    Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation
    Am Heart J. 2019;215:157-166.
    PubMed     Text format     Abstract available


  9. HENNESSY T, Soh L, Bowman M, Kurup R, et al
    The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.
    Am Heart J. 2019;215:62-69.
    PubMed     Text format     Abstract available


  10. CABEZA DE BACA T, Burroughs Pena MS, Slopen N, Williams D, et al
    Financial strain and ideal cardiovascular health in middle-aged and older women: Data from the Women's health study.
    Am Heart J. 2019;215:129-138.
    PubMed     Text format     Abstract available


  11. HALL TS, von Lueder TG, Zannad F, Rossignol P, et al
    Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.
    Am Heart J. 2019;215:83-90.
    PubMed     Text format     Abstract available


  12. CANNON CP, Khan I, Klimchak AC, Sanchez RJ, et al
    Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
    Am Heart J. 2019;216:30-41.
    PubMed     Text format     Abstract available


  13. GIBLETT JP, Clarke S, Zhao T, McCormick LM, et al
    The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial.
    Am Heart J. 2019;215:41-51.
    PubMed     Text format     Abstract available


  14. LENG W, Yang J, Fan X, Sun Y, et al
    Contemporary invasive management and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction in China: Findings from China Acute Myocardial Infarction (CAMI) Registry.
    Am Heart J. 2019;215:1-11.
    PubMed     Text format     Abstract available


  15. MANNER DH, Battioui C, Hantel S, Beasley BN, et al
    Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development.
    Am Heart J. 2019;215:178-186.
    PubMed     Text format     Abstract available


    May 2019
  16. CLAEYS MJ, Coussement P, Dubois P, Garcia-Dorado D, et al
    Clinical effects of cyclosporine in acute anterior myocardial infarction complicated by heart failure: A subgroup analysis of the CIRCUS Trial.
    Am Heart J. 2019 May 30. pii: S0002-8703(19)30129.
    PubMed     Text format    



  17. Correction to "Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease", [American Heart Journal (December 2018) 51-60].
    Am Heart J. 2019 May 29. pii: S0002-8703(19)30112.
    PubMed     Text format    


  18. FANAROFF AC, Vora AN, Chen AY, Mathews R, et al
    Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry.
    Am Heart J. 2019;214:184-193.
    PubMed     Text format     Abstract available


  19. YING T, Gill J, Webster A, Kim SJ, et al
    Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease-A trial protocol for the CARSK study.
    Am Heart J. 2019;214:175-183.
    PubMed     Text format     Abstract available


  20. PUYMIRAT E, Cayla G, Cottin Y, Elbaz M, et al
    Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015.
    Am Heart J. 2019;214:97-106.
    PubMed     Text format     Abstract available


  21. TOTH G, Brodmann M, Barbato E, Mangiacapra F, et al
    Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial).
    Am Heart J. 2019;214:107-112.
    PubMed     Text format     Abstract available


  22. SHARMA A, Hagstrom E, Wojdyla DM, Neely ML, et al
    Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.
    Am Heart J. 2019;215:106-113.
    PubMed     Text format     Abstract available


  23. MENTIAS A, Shantha G, Adeola O, Barnes GD, et al
    Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.
    Am Heart J. 2019;214:158-166.
    PubMed     Text format     Abstract available


  24. GAZIANO TA, Pandya A, Sy S, Jardim TV, et al
    Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Am Heart J. 2019;214:77-87.
    PubMed     Text format     Abstract available


  25. GELMAN A, Carlin JB, Nallamothu BK
    Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) and coronary stents: A case study in the analysis and reporting of clinical trials.
    Am Heart J. 2019;214:54-59.
    PubMed     Text format    


  26. DOUCET S, Jolicoeur EM, Serruys PW, Ragosta M 3rd, et al
    Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;214:9-17.
    PubMed     Text format     Abstract available


  27. RASMUSSEN LD, Winther S, Westra J, Isaksen C, et al
    Danish study of Non-Invasive testing in Coronary Artery Disease 2 (Dan-NICAD 2): Study design for a controlled study of diagnostic accuracy.
    Am Heart J. 2019;215:114-128.
    PubMed     Text format     Abstract available


    April 2019
  28. ZIMMERMANN FM, De Bruyne B, Pijls NHJ, Desai M, et al
    A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with
    Am Heart J. 2019;214:156-157.
    PubMed     Text format    


  29. QINTAR M, Hirai T, Arnold SV, Sheehy J, et al
    De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.
    Am Heart J. 2019;214:1-8.
    PubMed     Text format     Abstract available


  30. VAN DEN BERG MJ, van der Graaf Y, Deckers JW, de Kanter W, et al
    Smoking cessation and risk of recurrent cardiovascular events and mortality after a first manifestation of arterial disease.
    Am Heart J. 2019;213:112-122.
    PubMed     Text format     Abstract available


  31. AKERBLOM A, Wojdyla DM, Wallentin L, James SK, et al
    Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Am Heart J. 2019;213:57-65.
    PubMed     Text format     Abstract available


  32. GUTIERREZ JA, Bhatt DL, Banerjee S, Glorioso TJ, et al
    Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program.
    Am Heart J. 2019;213:47-56.
    PubMed     Text format     Abstract available


  33. SULLIVAN LT 2ND, Mulder H, Chiswell K, Shaw LK, et al
    Racial differences in long-term outcomes among black and white patients with drug-eluting stents.
    Am Heart J. 2019;214:46-53.
    PubMed     Text format     Abstract available


  34. DECKER PA, Larson NB, Bell EJ, Pankow JS, et al
    Increased hepatocyte growth factor levels over 2 years are associated with coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA).
    Am Heart J. 2019;213:30-34.
    PubMed     Text format     Abstract available


  35. VAN ZANDVOORT LJC, Masdjedi K, Tovar Forero MN, Lenzen MJ, et al
    Fractional flow reserve guided percutaneous coronary intervention optimization directed by high-definition intravascular ultrasound versus standard of care: Rationale and study design of the prospective randomized FFR-REACT trial.
    Am Heart J. 2019;213:66-72.
    PubMed     Text format     Abstract available


  36. VROEGINDEWEY MM, van den Berg VJ, Bouwens E, Akkerhuis KM, et al
    Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission.
    Am Heart J. 2019 Apr 6. pii: S0002-8703(19)30052.
    PubMed     Text format     Abstract available


  37. HSU S
    Response to the letter to the editor regarding the results of the retrospective study "Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock" published in the American Heart Journal.
    Am Heart J. 2019 Apr 6. pii: S0002-8703(19)30067.
    PubMed     Text format    


    March 2019
  38. SACCO A, Morici N, Oliva F
    Letter to the editor regarding the results of the retrospective study "Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock" published in the American Heart Journal.
    Am Heart J. 2019 Mar 23. pii: S0002-8703(19)30056.
    PubMed     Text format    


  39. JENSEN LO, Maeng M, Raungaard B, Engstrom T, et al
    Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomize
    Am Heart J. 2019;213:1-7.
    PubMed     Text format     Abstract available


  40. XING Y, Liu J, Hao Y, Liu J, et al
    Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CC
    Am Heart J. 2019;212:120-128.
    PubMed     Text format     Abstract available


  41. PUMILL CA, Bush CG, Greiner MA, Hall ME, et al
    Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study.
    Am Heart J. 2019;212:72-79.
    PubMed     Text format     Abstract available


  42. KIM C, Hong SJ, Shin DH, Kim BK, et al
    Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
    Am Heart J. 2019;212:45-52.
    PubMed     Text format     Abstract available


  43. ANGRAAL S, Gupta A, Khera R, Nasir K, et al
    Association of access to exercise opportunities and cardiovascular mortality.
    Am Heart J. 2019;212:152-156.
    PubMed     Text format     Abstract available


  44. YUDI MB, Clark DJ, Farouque O, Andrianopoulos N, et al
    Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention.
    Am Heart J. 2019;212:134-143.
    PubMed     Text format     Abstract available


  45. HOFFMANN U, Lu MT, Olalere D, Adami EC, et al
    Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
    Am Heart J. 2019;212:1-12.
    PubMed     Text format     Abstract available


  46. YANG N, Liu J, Liu J, Hao Y, et al
    Performance on management strategies with Class I Recommendation and A Level of Evidence among hospitalized patients with non-ST-segment elevation acute coronary syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-A
    Am Heart J. 2019;212:80-90.
    PubMed     Text format     Abstract available


  47. LIP GYH, Mauri L, Montalescot G, Ozkor M, et al
    Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
    Am Heart J. 2019;212:13-22.
    PubMed     Text format     Abstract available


    February 2019
  48. BULLUCK H, Frohlich GM, Nicholas JM, Mohdnazri S, et al
    Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
    Am Heart J. 2019;211:60-67.
    PubMed     Text format     Abstract available


  49. FINN MT, Redfors B, Karmpaliotis D, Kirtane AJ, et al
    Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
    Am Heart J. 2019;211:68-76.
    PubMed     Text format     Abstract available


  50. TANG X, Zhang D, He L, Wu N, et al
    Performance of atherosclerotic cardiovascular risk prediction models in a rural Northern Chinese population: Results from the Fangshan Cohort Study.
    Am Heart J. 2019;211:34-44.
    PubMed     Text format     Abstract available


    January 2019
  51. BLAKE SR, Shahzad A, Aggarwal SK, Kumar A, et al
    Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?
    Am Heart J. 2019;210:81-87.
    PubMed     Text format     Abstract available


  52. HERTZ JT, Madut DB, Tesha RA, William G, et al
    Knowledge of myocardial infarction symptoms and perceptions of self-risk in Tanzania.
    Am Heart J. 2019;210:69-74.
    PubMed     Text format     Abstract available


  53. FERRARI R, Ford I, Fox K, Marzilli M, et al
    A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline character
    Am Heart J. 2019;210:98-107.
    PubMed     Text format     Abstract available


  54. KOSMIDOU I, Redfors B, Chen S, Crowley A, et al
    C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;210:49-57.
    PubMed     Text format     Abstract available


  55. YEBYO HG, Aschmann HE, Kaufmann M, Puhan MA, et al
    Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    Am Heart J. 2019;210:18-28.
    PubMed     Text format     Abstract available


    December 2018
  56. DESCH S, Freund A, Graf T, Fichtlscherer S, et al
    Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial.
    Am Heart J. 2018;209:20-28.
    PubMed     Text format     Abstract available


  57. IBRAHIM NE, McCarthy CP, Shrestha S, Lyass A, et al
    Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study.
    Am Heart J. 2018;209:36-46.
    PubMed     Text format     Abstract available


  58. WANG X, Tian M, Zheng Z, Gao H, et al
    Rationale and design of a multicenter randomized trial to compare the graft patency between no-touch vein harvesting technique and conventional approach in coronary artery bypass graft surgery.
    Am Heart J. 2018;210:75-80.
    PubMed     Text format     Abstract available


  59. FORDYCE CB, Chen AY, Wang TY, Lucas J, et al
    Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2018;206:131-133.
    PubMed     Text format     Abstract available


    November 2018
  60. GIBSON CM, Kerneis M, Yee MK, Daaboul Y, et al
    The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
    Am Heart J. 2018;208:81-90.
    PubMed     Text format     Abstract available


  61. DOLL JA, Hellkamp AS, Thomas L, Fonarow GC, et al
    The association of pre- and posthospital medication adherence in myocardial infarction patients.
    Am Heart J. 2018;208:74-80.
    PubMed     Text format     Abstract available


  62. HEAD T, Henn L, Andreev VP, Herderick EE, et al
    Accelerated coronary atherosclerosis not explained by traditional risk factors in 13% of young individuals.
    Am Heart J. 2018;208:47-54.
    PubMed     Text format     Abstract available


  63. PAGIDIPATI NJ, Coles A, Hemal K, Lee KL, et al
    Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.
    Am Heart J. 2018;208:28-36.
    PubMed     Text format     Abstract available


  64. POLCWIARTEK C, Behrndtz P, Andersen AH, Bregendahl M, et al
    Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials.
    Am Heart J. 2018;208:21-27.
    PubMed     Text format    


  65. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    PubMed     Text format     Abstract available


  66. TRAN HV, Ash AS, Gore JM, Darling CE, et al
    Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction.
    Am Heart J. 2018;208:1-10.
    PubMed     Text format     Abstract available


    October 2018
  67. LAMBRAKIS K, French JK, Scott IA, Briffa T, et al
    The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design.
    Am Heart J. 2018;208:11-20.
    PubMed     Text format     Abstract available


  68. MUNKHAUGEN J, Ruddox V, Halvorsen S, Dammen T, et al
    BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
    Am Heart J. 2018;208:37-46.
    PubMed     Text format     Abstract available


  69. MACHLINE-CARRION MJ, Soares RM, Damiani LP, Campos VB, et al
    Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial.
    Am Heart J. 2018;207:40-48.
    PubMed     Text format     Abstract available


  70. PAGIDIPATI NJ, Mudrick DW, Chiswell K, Brucker A, et al
    Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease.
    Am Heart J. 2018;206:51-60.
    PubMed     Text format     Abstract available


    September 2018
  71. PRADHAN AD, Paynter NP, Everett BM, Glynn RJ, et al
    Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Am Heart J. 2018;206:80-93.
    PubMed     Text format     Abstract available


  72. GUEDENEY P, Baber U, Claessen B, Aquino M, et al
    Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
    Am Heart J. 2018;207:10-18.
    PubMed     Text format     Abstract available


  73. HARRISON RW, Radhakrishnan V, Allen JC Jr, Lam PS, et al
    The East-West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2018;206:61-71.
    PubMed     Text format     Abstract available


  74. CANNON CP, McGuire DK, Pratley R, Dagogo-Jack S, et al
    Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
    Am Heart J. 2018;206:11-23.
    PubMed     Text format     Abstract available


    August 2018
  75. ELGENDY IY, Mansoor H, Li Q, Guo Y, et al
    Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.
    Am Heart J. 2018 Aug 30. pii: S0002-8703(18)30252.
    PubMed     Text format     Abstract available


  76. LEE J, Nakanishi R, Li D, Shaikh K, et al
    Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30249.
    PubMed     Text format     Abstract available


  77. ALFONSO F, Cuesta J, Garcia-Guimaraes M, Gonzalez-Barthol E, et al
    Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30250.
    PubMed     Text format    


  78. KANG DY, Wong YTA, Park DW, Park SJ, et al
    The authors reply: Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 23. pii: S0002-8703(18)30251.
    PubMed     Text format    


  79. MAURI L, Kirtane AJ, Windecker S, Yeh RW, et al
    Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
    Am Heart J. 2018;205:110-117.
    PubMed     Text format     Abstract available


  80. EINDHOVEN DC, Wu HW, Kremer SWF, van Erkelens JA, et al
    Mortality differences in acute myocardial infarction patients in the Netherlands: The weekend-effect.
    Am Heart J. 2018;205:70-76.
    PubMed     Text format    


  81. CHUNG CJ, Kirtane AJ, Zhang Y, Witzenbichler B, et al
    Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents.
    Am Heart J. 2018;205:77-86.
    PubMed     Text format     Abstract available


  82. LAURSEN PN, Holmvang L, Lonborg J, Kober L, et al
    Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study.
    Am Heart J. 2018;204:128-138.
    PubMed     Text format     Abstract available


  83. MACK MJ, Abraham WT, Lindenfeld J, Bolling SF, et al
    Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
    Am Heart J. 2018;205:1-11.
    PubMed     Text format     Abstract available


    July 2018
  84. BURGESS SN, French JK, Nguyen TL, Leung M, et al
    The impact of incomplete revascularization on early and late outcomes in ST-elevation myocardial infarction.
    Am Heart J. 2018;205:31-41.
    PubMed     Text format     Abstract available


  85. PAGIDIPATI NJ, Hellkamp AS, Sharma PP, Wang TY, et al
    High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States.
    Am Heart J. 2018;204:151-155.
    PubMed     Text format     Abstract available


  86. MORICI N, Oliva F, Ajello S, Stucchi M, et al
    Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial.
    Am Heart J. 2018 Jul 20. pii: S0002-8703(18)30217.
    PubMed     Text format     Abstract available


  87. STEVENS ER, Farrell D, Jumkhawala SA, Ladapo JA, et al
    Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review.
    Am Heart J. 2018;204:17-33.
    PubMed     Text format     Abstract available


  88. GIBBONS RJ, Weintraub WS, Brindis RG
    Moving from volume to value for revascularization in stable ischemic heart disease: A review.
    Am Heart J. 2018 Jul 10. pii: S0002-8703(18)30108.
    PubMed     Text format     Abstract available


  89. HUGELSHOFER S, Roffi M, Witassek F, Eberli FR, et al
    Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention.
    Am Heart J. 2018;204:34-42.
    PubMed     Text format     Abstract available


  90. GUALANDRO DM, Puelacher C, LuratiBuse G, Lampart A, et al
    Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery.
    Am Heart J. 2018;203:67-73.
    PubMed     Text format     Abstract available


  91. GNANENTHIRAN SR, Yiannikas J, Lowe HC, Brieger D, et al
    Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice.
    Am Heart J. 2018;203:74-81.
    PubMed     Text format     Abstract available


  92. RYMER JA, Tempelhof MW, Clare RM, Pieper KS, et al
    Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.
    Am Heart J. 2018;201:103-110.
    PubMed     Text format     Abstract available


  93. VENETSANOS D, Lawesson SS, James S, Koul S, et al
    Bivalirudin versus heparin with primary percutaneous coronary intervention.
    Am Heart J. 2018;201:9-16.
    PubMed     Text format     Abstract available


  94. INOHARA T, Pieper K, Wojdyla DM, Patel MR, et al
    Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.
    Am Heart J. 2018;201:25-32.
    PubMed     Text format     Abstract available


    June 2018
  95. XU H, Faxen J, Szummer K, Trevisan M, et al
    Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction.
    Am Heart J. 2018;205:53-62.
    PubMed     Text format     Abstract available


  96. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    PubMed     Text format     Abstract available


  97. PAOLI G, Notarangelo MF, Mattioli M, La Sala R, et al
    ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program.
    Am Heart J. 2018;203:12-16.
    PubMed     Text format    


  98. GREEN JB, Hernandez AF, D'Agostino RB, Granger CB, et al
    Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
    Am Heart J. 2018;203:30-38.
    PubMed     Text format     Abstract available


  99. ATZEMA CL, Dorian P, Fang J, Tu JV, et al
    A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study.
    Am Heart J. 2018;203:85-92.
    PubMed     Text format     Abstract available


  100. HJORT M, Lindahl B, Baron T, Jernberg T, et al
    Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries.
    Am Heart J. 2018;200:60-66.
    PubMed     Text format     Abstract available


  101. ISRAR MZ, Heaney LM, Ng LL, Suzuki T, et al
    B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction.
    Am Heart J. 2018;200:37-43.
    PubMed     Text format     Abstract available


  102. CAPLICE NM, DeVoe MC, Choi J, Dahly D, et al
    Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI).
    Am Heart J. 2018;200:110-117.
    PubMed     Text format     Abstract available


  103. CARSON JL, Stanworth SJ, Alexander JH, Roubinian N, et al
    Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease.
    Am Heart J. 2018;200:96-101.
    PubMed     Text format     Abstract available


  104. ELFWEN L, Lagedal R, James S, Jonsson M, et al
    Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival.
    Am Heart J. 2018;200:90-95.
    PubMed     Text format     Abstract available


  105. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    PubMed     Text format     Abstract available


  106. LATTUCA B, Barber-Chamoux N, Alos B, Sfaxi A, et al
    Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: A randomized trial.
    Am Heart J. 2018;200:67-74.
    PubMed     Text format     Abstract available


  107. PASTORI D, Pignatelli P, Cribari F, Carnevale R, et al
    Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.
    Am Heart J. 2018;200:32-36.
    PubMed     Text format     Abstract available


  108. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    PubMed     Text format     Abstract available


    May 2018
  109. ITSIOPOULOS C, Kucianski T, Mayr HL, van Gaal WJ, et al
    The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial): A randomized clinical trial in secondary prevention of coronary heart disease in a multiethnic Australian population: Study protocol.
    Am Heart J. 2018;203:4-11.
    PubMed     Text format     Abstract available


  110. VARDENY O, Udell JA, Joseph J, Farkouh ME, et al
    High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.
    Am Heart J. 2018;202:97-103.
    PubMed     Text format     Abstract available


  111. HOLMEN J, Herlitz J, Axelsson C
    Immediate coronary intervention in prehospital cardiac arrest-Aiming to save lives.
    Am Heart J. 2018 May 22. pii: S0002-8703(18)30158.
    PubMed     Text format    


  112. LI S, Blumenthal JA, Shi C, Millican D, et al
    I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale.
    Am Heart J. 2018;202:109-115.
    PubMed     Text format     Abstract available


  113. JAKOBSEN L, Christiansen EH, Maeng M, Kristensen SD, et al
    Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian
    Am Heart J. 2018;202:49-53.
    PubMed     Text format     Abstract available


  114. HSU S, Kambhampati S, Sciortino CM, Russell SD, et al
    Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock.
    Am Heart J. 2018;199:181-191.
    PubMed     Text format     Abstract available


  115. WANG A, Wu A, Wojdyla D, Lopes RD, et al
    Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
    Am Heart J. 2018;199:150-155.
    PubMed     Text format     Abstract available


  116. GIANOS E, Schoenthaler A, Guo Y, Zhong J, et al
    Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.
    Am Heart J. 2018;199:37-43.
    PubMed     Text format     Abstract available


  117. BRINKLEY DM JR, Ho KKL, Drazner MH, Kociol RD, et al
    The prognostic value of the relationship between right atrial and pulmonary capillary wedge pressure in diverse cardiovascular conditions.
    Am Heart J. 2018;199:31-36.
    PubMed     Text format     Abstract available


  118. MARWICK TH, Whitmore K, Nicholls SJ, Stanton T, et al
    Rationale and design of a trial to personalize risk assessment in familial coronary artery disease.
    Am Heart J. 2018;199:22-30.
    PubMed     Text format     Abstract available


  119. THEODORAKIS MJ, Coleman RL, Feng H, Chan J, et al
    Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
    Am Heart J. 2018;199:170-175.
    PubMed     Text format    


  120. LACHMAN S, Terbraak MS, Limpens J, Jorstad H, et al
    The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis.
    Am Heart J. 2018;199:163-169.
    PubMed     Text format     Abstract available


  121. GHARACHOLOU SM, Ijioma NN, Lennon RJ, Rihal CS, et al
    Characteristics and long term outcomes of patients with acute coronary syndromes due to culprit left main coronary artery disease treated with percutaneous coronary intervention.
    Am Heart J. 2018;199:156-162.
    PubMed     Text format     Abstract available


  122. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
    Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Am Heart J. 2018;199:137-143.
    PubMed     Text format     Abstract available


  123. BOSWORTH HB, Olsen MK, McCant F, Stechuchak KM, et al
    Telemedicine cardiovascular risk reduction in veterans: The CITIES trial.
    Am Heart J. 2018;199:122-129.
    PubMed     Text format     Abstract available


  124. KANG J, Koo BK, Hu X, Lee JM, et al
    Comparison of Fractional FLow Reserve And Intravascular ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients with InteRmediate Stenosis (FLAVOUR): Rationale and design of a randomized clinical trial.
    Am Heart J. 2018;199:7-12.
    PubMed     Text format     Abstract available


  125. VETROVEC GW, Anderson M, Schreiber T, Popma J, et al
    The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure.
    Am Heart J. 2018;199:115-121.
    PubMed     Text format     Abstract available


    April 2018
  126. PATEL KK, Arnold SV, Chan PS, Tang Y, et al
    Validation of the Seattle angina questionnaire in women with ischemic heart disease.
    Am Heart J. 2018;201:117-123.
    PubMed     Text format     Abstract available


  127. SPRUILL TM, Reynolds HR, Dickson VV, Shallcross AJ, et al
    Telephone-based mindfulness training to reduce stress in women with myocardial infarction: Rationale and design of a multicenter randomized controlled trial.
    Am Heart J. 2018;202:61-67.
    PubMed     Text format     Abstract available


  128. O'NEILL WW, Grines C, Schreiber T, Moses J, et al
    Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device.
    Am Heart J. 2018;202:33-38.
    PubMed     Text format     Abstract available


  129. PENNY WF, Henry TD, Watkins MW, Patel AN, et al
    Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Am Heart J. 2018;201:111-116.
    PubMed     Text format     Abstract available


  130. MUHLESTEIN JB, May HT, Galenko O, Knowlton KU, et al
    GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.
    Am Heart J. 2018;202:27-32.
    PubMed     Text format     Abstract available


  131. RAVAL AN, Cook TD, Duckers HJ, Johnston PV, et al
    The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study d
    Am Heart J. 2018;201:141-148.
    PubMed     Text format     Abstract available


  132. FORD TJ, Corcoran D, Oldroyd KG, McEntegart M, et al
    Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial.
    Am Heart J. 2018;201:86-94.
    PubMed     Text format     Abstract available


  133. RYMER JA, Kaltenbach LA, Anstrom KJ, Fonarow GC, et al
    Hospital evaluation of health literacy and associated outcomes in patients after acute myocardial infarction.
    Am Heart J. 2018;198:97-107.
    PubMed     Text format     Abstract available


  134. CHEW DS, Wilton SB, Kavanagh K, Southern DA, et al
    Left ventricular ejection fraction reassessment post-myocardial infarction: Current clinical practice and determinants of adverse remodeling.
    Am Heart J. 2018;198:91-96.
    PubMed     Text format     Abstract available


  135. KINNAIRD T, Cockburn J, Gallagher S, Choudhury A, et al
    Temporal changes in radial access use, associates and outcomes in patients undergoing PCI using rotational atherectomy between 2007 and 2014: results from the British Cardiovascular Intervention Society national database.
    Am Heart J. 2018;198:46-54.
    PubMed     Text format     Abstract available


  136. CACOUB P, Nahon P, Layese R, Blaise L, et al
    Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
    Am Heart J. 2018;198:4-17.
    PubMed     Text format     Abstract available


  137. BISHAWI M, Hattler B, Almassi GH, Spertus JA, et al
    Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the Randomized On/Off Bypass (ROOBY) trial.
    Am Heart J. 2018;198:33-38.
    PubMed     Text format     Abstract available


  138. AL RIFAI M, Greenland P, Blaha MJ, Michos ED, et al
    Factors of health in the protection against death and cardiovascular disease among adults with subclinical atherosclerosis.
    Am Heart J. 2018;198:180-188.
    PubMed     Text format     Abstract available


  139. NAVAR AM, Pencina MJ, Mulder H, Elias P, et al
    Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles.
    Am Heart J. 2018;198:18-24.
    PubMed     Text format     Abstract available


  140. TOMASELLI G, Roach WH, Pina IL, Oster ME, et al
    Government continues to have an important role in promoting cardiovascular health.
    Am Heart J. 2018;198:160-165.
    PubMed     Text format    


  141. BOWMAN L, Mafham M, Stevens W, Haynes R, et al
    ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
    Am Heart J. 2018;198:135-144.
    PubMed     Text format     Abstract available


  142. BATCHELOR W, Dahya V, McGee D, Katopodis J, et al
    Ultrahigh-resolution ultrasound characterization of access site trauma and intimal hyperplasia following use of a 7F sheathless guide versus 6F sheath/guide combination for transradial artery PCI: Results of the PRAGMATIC trial.
    Am Heart J. 2018;198:75-83.
    PubMed     Text format     Abstract available


  143. VAN DER HEIJDEN LC, Kok MM, Zocca P, Jessurun GAJ, et al
    Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.
    Am Heart J. 2018;198:25-32.
    PubMed     Text format     Abstract available


  144. BERGMEIJER TO, Reny JL, Pakyz RE, Gong L, et al
    Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).
    Am Heart J. 2018;198:152-159.
    PubMed     Text format     Abstract available


  145. BERWANGER O, de Barros E Silva PGM, Dall Orto FTC, de Andrade PB, et al
    Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial.
    Am Heart J. 2018;198:129-134.
    PubMed     Text format     Abstract available


    March 2018
  146. BOHULA EA, Scirica BM, Fanola C, Inzucchi SE, et al
    Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Am Heart J. 2018;202:39-48.
    PubMed     Text format     Abstract available


  147. BERWANGER O, Nicolau JC, Carvalho AC, Jiang L, et al
    Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
    Am Heart J. 2018;202:89-96.
    PubMed     Text format     Abstract available


  148. LOOP MS, McClure LA, Levitan EB, Al-Hamdan MZ, et al
    Fine particulate matter and incident coronary heart disease in the REGARDS cohort.
    Am Heart J. 2018;197:94-102.
    PubMed     Text format     Abstract available


  149. SHAVADIA JS, French W, Hellkamp AS, Thomas L, et al
    Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program.
    Am Heart J. 2018;197:9-17.
    PubMed     Text format     Abstract available


  150. HAYS AG, Iantorno M, Schar M, Lai S, et al
    The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.
    Am Heart J. 2018;197:85-93.
    PubMed     Text format     Abstract available


  151. SONG YB, Oh SK, Oh JH, Im ES, et al
    Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Am Heart J. 2018;197:77-84.
    PubMed     Text format     Abstract available


  152. EGGERS KM, Jernberg T, Lindahl B
    High-sensitivity cardiac troponin T, left ventricular function, and outcome in non-ST elevation acute coronary syndrome.
    Am Heart J. 2018;197:70-76.
    PubMed     Text format     Abstract available


  153. LAGEDAL R, Elfwen L, James S, Oldgren J, et al
    Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study.
    Am Heart J. 2018;197:53-61.
    PubMed     Text format     Abstract available


  154. WONG YTA, Kang DY, Lee JB, Rha SW, et al
    Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial.
    Am Heart J. 2018;197:35-42.
    PubMed     Text format     Abstract available


  155. REDFORS B, Genereux P, Witzenbichler B, Maehara A, et al
    Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Am Heart J. 2018;197:142-149.
    PubMed     Text format     Abstract available


  156. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    PubMed     Text format     Abstract available


  157. HWANG D, Park KW, Lee JM, Rhee TM, et al
    Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
    Am Heart J. 2018;197:103-112.
    PubMed     Text format     Abstract available


  158. SHERWOOD MW, Lopes RD, Sun JL, Liaw D, et al
    Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
    Am Heart J. 2018;197:1-8.
    PubMed     Text format     Abstract available


  159. CZARNY MJ, Miller JM, Naiman DQ, Hwang CW, et al
    Nonprimary PCI at hospitals without cardiac surgery on-site: Consistent outcomes for all?
    Am Heart J. 2018;197:18-26.
    PubMed     Text format     Abstract available


    February 2018
  160. LENG WX, Yang J, Li W, Wang Y, et al
    Rationale and design of the DEAR-OLD trial: Randomized evaluation of routinely Deferred versus EARly invasive strategy in elderly patients of 75 years or OLDer with non-ST-elevation myocardial infarction.
    Am Heart J. 2018;196:65-73.
    PubMed     Text format     Abstract available


  161. BAGAI A, Goodman SG, Cantor WJ, Vicaut E, et al
    Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study.
    Am Heart J. 2018;196:56-64.
    PubMed     Text format     Abstract available


  162. GUIMARAES PO, Leonardi S, Huang Z, Wallentin L, et al
    Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2018;196:28-35.
    PubMed     Text format     Abstract available


  163. KILIC S, Fabris E, Van't Hof AWJ, Hamm CW, et al
    Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial.
    Am Heart J. 2018;196:1-8.
    PubMed     Text format     Abstract available


  164. DUPRE ME, Xu H, Granger BB, Lynch SM, et al
    Access to routine care and risks for 30-day readmission in patients with cardiovascular disease.
    Am Heart J. 2018;196:9-17.
    PubMed     Text format     Abstract available


  165. MCCARTHY CP, McEvoy JW, Januzzi JL Jr.
    Biomarkers in stable coronary artery disease.
    Am Heart J. 2018;196:82-96.
    PubMed     Text format     Abstract available


  166. ANYANWAGU U, Mamza J, Donnelly R, Idris I, et al
    Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
    Am Heart J. 2018;196:18-27.
    PubMed     Text format     Abstract available


  167. KHAZANIE P, Al-Khatib SM, Wang TY, Crowley MJ, et al
    Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs.
    Am Heart J. 2018;196:170-177.
    PubMed     Text format     Abstract available


  168. CROWLEY MJ, Al-Khatib SM, Wang TY, Khazanie P, et al
    How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?
    Am Heart J. 2018;196:163-169.
    PubMed     Text format     Abstract available


  169. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
    Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
    Am Heart J. 2018;196:105-112.
    PubMed     Text format     Abstract available


  170. LAURIDSEN KG, Schmidt AS, Adelborg K, Bach L, et al
    Effects of hyperoxia on myocardial injury following cardioversion-A randomized clinical trial.
    Am Heart J. 2018;196:97-104.
    PubMed     Text format     Abstract available


  171. SCIAHBASI A, Frigoli E, Sarandrea A, Calabro P, et al
    Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study.
    Am Heart J. 2018;196:113-118.
    PubMed     Text format     Abstract available


    January 2018
  172. AFANA M, Gurm HS, Seth M, Frazier KM, et al
    Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Am Heart J. 2018;195:99-107.
    PubMed     Text format     Abstract available


  173. TARANTINI G, Ueshima D, D'Amico G, Masiero G, et al
    Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis.
    Am Heart J. 2018;195:78-85.
    PubMed     Text format     Abstract available


  174. ISSA OM, Roberts R, Mark DB, Boineau R, et al
    Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
    Am Heart J. 2018;195:70-77.
    PubMed     Text format     Abstract available


  175. BOSSARD M, Binbraik Y, Beygui F, Pitt B, et al
    Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials.
    Am Heart J. 2018;195:60-69.
    PubMed     Text format     Abstract available


  176. LIU E, Hsueh L, Kim H, Vidovich MI, et al
    Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.
    Am Heart J. 2018;195:39-49.
    PubMed     Text format     Abstract available


  177. HESS PL, Kennedy K, Cowherd M, Virani SS, et al
    Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
    Am Heart J. 2018;195:151-152.
    PubMed     Text format    


  178. VEMULAPALLI S, Holmes DR Jr, Dai D, Matsouaka R, et al
    Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: A report from the STS/ACC TVT Registry.
    Am Heart J. 2018;195:1-13.
    PubMed     Text format     Abstract available


    December 2017
  179. ILIESCU CA, Cilingiroglu M, Giza DE, Rosales O, et al
    "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).
    Am Heart J. 2017;194:83-91.
    PubMed     Text format     Abstract available


  180. QADERDAN K, Vos GA, McAndrew T, Steg PG, et al
    Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
    Am Heart J. 2017;194:73-82.
    PubMed     Text format     Abstract available


  181. INOHARA T, Numasawa Y, Higashi T, Ueda I, et al
    Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
    Am Heart J. 2017;194:61-72.
    PubMed     Text format     Abstract available


  182. DESAI NR, Kennedy KF, Cohen DJ, Connolly T, et al
    Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry(R)-Get With The Guidelines (GWTG)(R).
    Am Heart J. 2017;194:16-24.
    PubMed     Text format     Abstract available


  183. HIRJI SA, Stevens SR, Shaw LK, Campbell EC, et al
    Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease.
    Am Heart J. 2017;194:116-124.
    PubMed     Text format     Abstract available


  184. GO AS, Fan D, Sung SH, Inveiss AI, et al
    Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study.
    Am Heart J. 2017;194:25-38.
    PubMed     Text format     Abstract available


    November 2017
  185. MUSTO C, De Felice F, Rigattieri S, Chin D, et al
    Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study.
    Am Heart J. 2017;193:63-69.
    PubMed     Text format     Abstract available


  186. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
    Am Heart J. 2017;193:46-54.
    PubMed     Text format     Abstract available


  187. AKINTOYE E, Briasoulis A, Afonso L
    Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification.
    Am Heart J. 2017;193:95-103.
    PubMed     Text format     Abstract available


  188. LEE PH, Lee JY, Lee CW, Han S, et al
    Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
    Am Heart J. 2017;193:76-83.
    PubMed     Text format     Abstract available


  189. DOROS G, Massaro JM, Kandzari DE, Waksman R, et al
    Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
    Am Heart J. 2017;193:35-45.
    PubMed     Text format     Abstract available


  190. CHIANG MH, Wu HH, Shih CJ, Chen YT, et al
    Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients.
    Am Heart J. 2017;193:1-7.
    PubMed     Text format     Abstract available


  191. SHADDY R, Canter C, Halnon N, Kochilas L, et al
    Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Am Heart J. 2017;193:23-34.
    PubMed     Text format     Abstract available


    October 2017
  192. WAKSMAN R, Torguson R, Spad MA, Garcia-Garcia H, et al
    The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale.
    Am Heart J. 2017;192:98-104.
    PubMed     Text format     Abstract available


  193. JESSEE R, Peart E, Beineke P, Rosenberg S, et al
    Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease.
    Am Heart J. 2017;192:13-18.
    PubMed     Text format     Abstract available


  194. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    PubMed     Text format     Abstract available


  195. ALBERT MA, Durazo EM, Slopen N, Zaslavsky AM, et al
    Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics.
    Am Heart J. 2017;192:1-12.
    PubMed     Text format     Abstract available


    September 2017
  196. WALLERT J, Held C, Madison G, Olsson EM, et al
    Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDEHEART national registry study.
    Am Heart J. 2017;191:12-20.
    PubMed     Text format     Abstract available


  197. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
    Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
    Am Heart J. 2017;191:65-74.
    PubMed     Text format     Abstract available


  198. FARB A, Zuckerman BD
    Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective.
    Am Heart J. 2017;191:62-64.
    PubMed     Text format    


  199. REN HY, Khera A, de Lemos JA, Ayers CR, et al
    Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population.
    Am Heart J. 2017;191:55-61.
    PubMed     Text format     Abstract available


  200. KIM Y, Soffler M, Paradise S, Jelani QU, et al
    Depression is associated with recurrent chest pain with or without coronary artery disease: A prospective cohort study in the emergency department.
    Am Heart J. 2017;191:47-54.
    PubMed     Text format     Abstract available


  201. WEI J, Mehta PK, Grey E, Garberich RF, et al
    Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
    Am Heart J. 2017;191:30-36.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: